



To NASDAQ OMX Copenhagen A/S
Announcement no. 07-14 / Copenhagen, April 24, 2014

Topotarget A/S
Symbion
Fruebjergvej 3
DK-2100 Copenhagen
Denmark
T: +45 39 17 83 92
E: enquiries@topotarget.com
Comp reg.: 2569 5771
www.topotarget.com

Passing on Annual General Meeting

Topotarget A/S today held its annual general meeting at Symbion, Fruebjergvej 3, DK-2100 Copenhagen, Denmark.

At the meeting, Chairman of the Board, Bo Jesper Hansen, and Chief Executive Officer, Anders Vadsholt, gave a report on the company's activities during the past year. The audited annual report was adopted and a resolution was passed to discharge the Board of Directors and the management from liability. It was resolved that the loss for the year of DKK 35 million be carried forward to next year through recognition in retained earnings.

Bo Jesper Hansen, Anker Lundemose, Ingelise Saunders, Jeffrey H. Buchalter, Per Samuelsson, Gisela Schwab, and Karsten Witt were re-elected for a period of one year. Deloitte, Statsautoriseret Revisionspartnerselskab was re-appointed as the company's auditors.

The proposals under agenda items 6.1.1, 6.1.2, and 6.1.3, put forward by Topotarget shareholder Kjeld Beyer, were not adopted.

The Board of Directors was authorized to purchase treasury shares within a limit of 10% of the company's share capital at a price corresponding to the listed price plus/less 5% at the time of the purchase. The Chairman of the meeting was authorized to apply for registration of the resolutions passed and to make any such amendments thereto as may be required by the Danish Business Authority as a condition for registration or approval.

Anders Vadsholt and Bo Jesper Hansen provided a short update on the intended merger with BioAlliance Pharma and answered questions.

Immediately after the general meeting the Board of Directors convened and elected Bo Jesper Hansen as Chairman.

Topotarget A/S

For further information, please contact:
Anders Vadsholt, CEO – direct: +45 39178345

Background information

About Topotarget

Topotarget (NASDAQ OMX: TOPO) is a Scandinavian-based biopharmaceutical company headquartered in Copenhagen, Denmark, dedicated to the clinical development and registration of oncology products. In collaboration with Spectrum Pharmaceuticals, Inc., Topotarget focuses on the development of its lead drug candidate, belinostat, which has shown positive results in the treatment of hematological malignancies and solid tumors, obtained by both mono- and combination therapy. For more information, please refer to www.topotarget.com.

Topotarget Safe Harbor Statement

This announcement may contain forward-looking statements, including statements about Topotarget A/S' expectations to the progression of Topotarget A/S' clinical pipeline and with respect to cash burn guidance. Such statements are subject to risks and uncertainties of which many are outside the control of Topotarget A/S, and which could cause actual results to differ materially from those described. Topotarget A/S disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by Danish law.